Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy

Abstract

The growing interest and investments in targeted radionuclide therapy (TRT) have expanded research efforts across preclinical and clinical domains. Researchers from diverse fields, including nuclear medicine, radiochemistry, radiopharmacy, radiotherapy, biology, and physics, are increasingly focusing on TRT. Despite this, a lack of standardization in preclinical radiobiological studies hinders the evaluation and comparison of therapeutic radiopharmaceuticals across laboratories. Recognizing this, participants at the second International Workshop on Radiobiology of Molecular Radiotherapy, held in London, UK, in March 2023, emphasized the need for a consensus on nomenclature and standardized reporting guidelines in this field. The recommendations outlined here aim to address this gap by promoting consistent reporting. By adopting these standards, we hope to enhance the reproducibility, inter-laboratory comparability and visibility of preclinical TRT research, ultimately accelerating progress and amplifying its impact on the field and clinic.